MOLOGEN AG Achieves Patient Enrollment Goal for Small Cell Lung Cancer IMPULSE Study with Developmental Drug MGN1703
Lung Cancer, News
MOLOGEN AG, a biotechnology company focused on the development of cancer and infectious disease immunotherapies, has announced that its IMPULSE lung cancer clinical study has achieved its recruitment goal of ... Read more